The Young People Fighting AIDS and BIG PHARMA
The Young People Fighting AIDS and BIG PHARMA
High-Level UN Initiative On Global Public Health Gap Holds Landmark Hearing
High-Level UN Initiative On Global Public Health Gap Holds Landmark Hearing
GSK expand access to medicines but much more needs to be done
GlaxoSmithKline (GSK) recently announced in a press release that it would be expanding its graduated approach to patents and intellectual property to widen access to medicines in the world’s poorest countries. GSK have said that they won’t file patents in Least...
Me Too Drugs
Fojo T et al. “Unintended consequences of expensive cancer therapeutics – the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity” JAMA Otolaryngology Head and Neck Surgery (2014). Prescrire (2014); 34 (364):132-136 ‘New drugs...
Gilead admit that high prices aren’t to cover R&D
ACCESS DENIED: Report of the Inquiry of the All Party Parliamentary Group on HIV and AIDS into access to medicines in the developing world December 2014 http://impactaids.co.uk/wp-content/uploads/ACCESS-DENIED-APPG-Report-1.12.14.pdf p.39
The CEWG report
Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (2012) “Research and Development to meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination”...
One in four HIV/AIDS treatments would not exists without university research
Sampat, B. N. (2009). Academic patents and access to medicines in developing countries. American journal of public health, 99(1), 9-17.
Between 1/4 and 1/3 of new drugs originate in a university lab
Kneller, R. (2010). The importance of new companies for drug discovery: origins of a decade of new drugs. Nature Reviews Drug Discovery, 9(11), 867-882.